AGER and early-onset autosomal dominant Alzheimer disease: For instance, Azeliragon, the orally bioavailable small molecule inhibitor of RAGE, was used as an agent in preclinical studies of diabetic complications (Ma et al, 2023) or clinical studies of Alzheimer’s disease (Galasko et al, 2014; Burstein et al, 2014) and showed efficacy.